02.01.07
Cobra Biomanufacturing has entered into an agreement with Pharmexa for the manufacture of the protein vaccine PX107 for use in Phase I trials for bone disorders. The program will include cell banking, process development and GMP manufacture. Cobra will manufacture the protein at its GMP facility in Oxford, UK.
PX107 utilizes Pharmexa’s AutoVac active immunotherapy technology. Preclinical development has shown PX107 induces a potent polyclonal antibody response towards the protein RANKL, which is increased or imbalanced in the body in diseases such as osteoporosis, rheumatoid arthritis and bone metastasis with pathological bone destruction.
David Thatcher, chief executive officer of Cobra Biomanufacturing, commented, “We very much look forward to providing Pharmexa with our GMP manufacturing expertise to produce their promising vaccine candidate, PX107. The product will be manufactured at our recently expanded Oxford site."
PX107 utilizes Pharmexa’s AutoVac active immunotherapy technology. Preclinical development has shown PX107 induces a potent polyclonal antibody response towards the protein RANKL, which is increased or imbalanced in the body in diseases such as osteoporosis, rheumatoid arthritis and bone metastasis with pathological bone destruction.
David Thatcher, chief executive officer of Cobra Biomanufacturing, commented, “We very much look forward to providing Pharmexa with our GMP manufacturing expertise to produce their promising vaccine candidate, PX107. The product will be manufactured at our recently expanded Oxford site."